美股新聞 標題聯播 · 近 24 小時 337 則 · 29 個來源 · 最新 9/20 04:53
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · INVA近 30 天 1 則 · 第 1 / 1 頁
- Innoviva to Participate in Upcoming Investor Conferences
- Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award
- How Innoviva’s Q2 Loss and Aggressive Buybacks Could Reshape Capital Allocation for INVA Investors
- Innoviva (INVA) Q2 Earnings and Revenues Top Estimates
- Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
- AbbVie (ABBV) Q2 Earnings and Revenues Beat Estimates
- Is Innoviva (INVA) One of the Best Cheap Small Cap Stocks to Buy Now?
- AbbVie (ABBV) Moves 4.2% Higher: Will This Strength Last?
- Bayer (BAYRY) Moves 17.0% Higher: Will This Strength Last?
- Innoviva, Inc. (INVA) Launches Nortiva Bio to Advance Long-Acting Oral Drug Platform
- Innoviva Specialty Therapeutics (INVA) Partners With Dr. Reddy’s to Expand XACDURO Access Internationally
- Nortiva Bio Launches to Develop Long-Acting Oral Medicines
- Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets
- Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More
- Innoviva, Inc. (INVA) Draws Bullish View from Cantor on Recurring Royalty Strength
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。